Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Drugstore Chains
Sector Retail Trade
Employees 50,000
CEO Ms. Heyward R. Donigan
Address 30 Hunter Lane , Camp Hill, PA 17011-2400
Phone 1.717.761.2633
Website www.riteaid.com

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through following segments: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Camp Hill, PA.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Rite Aid Corp. -18.12% 31.72%
Missfresh Ltd. n/a n/a
Shoe Carnival, Inc. 5.03% 78.32%
Zumiez, Inc. -3.01% 38.87%
The Honest Co., Inc. -34.43% n/a

Statement Summary

as of 4:10 ET PM 09/16/2021
Total Assets (MRQ) 9.4 B
Total Liabilities (MRQ) 8.7 B
Shareholders’ Equity (MRQ) 604.0 M
Total Revenue (Annual) 6.2 B
Net Income (Annual) -13.1 M

Earnings And Estimates

as of 4:10 ET PM 09/16/2021

Current Qtr EPS Estimate -0.46
Current FY EPS Estimate -0.63
Long Term EPS Growth Estimate 30.92
Next Expected Earnings Date //

RAD vs S&P 500

as of 09/16/2021
Relative To
S&P 500
RAD
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:10 ET PM 09/16/2021
Fiscal Quarter Estimate Actual Surprise
05/2021 0.28 0.38 +35.81%
02/2021 -1.14 -0.78 -31.58%
11/2020 0.01 0.40 +4,663.04%
08/2020 0.01 0.25 +3,363.56%
05/2020 -0.38 -0.04 -89.45%
02/2020 -0.15 -0.37 +152.67%
11/2019 0.07 0.54 +673.04%
08/2019 0.02 0.12 +468.18%

Financial Strength

as of 4:10 ET PM 09/16/2021
Pre-Tax Margin -0.20
Net Margin 82.43
Operating Margin 1.32
Return On Equity -6.64
Return On Assets -0.43
Inventory Turnover (TTM) 10.38
Sales Growth (MRQ) n/a

Ratios

as of 4:10 PM ET 09/16/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 1.59
Price/Cash Flow (TTM) 2.88
Book Value (MRQ) 10.96
Quick Ratio (MRQ) 0.67
Current Ratio (MRQ) 1.35
Total Debt/Equity (MRQ) 10.48

Short Interest

as of 4:10 PM ET 09/17/2021
% Short - 17.56%
% Remaining Float - 82.44%
Current Last Month
Short Interest Date 08/31/2021 08/13/2021
Short Interest Shares 9,377,451 11,152,278
Short Interest Ratio 5.5 6.9
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:10 ET PM 09/16/2021
Current Qtr
(08/2021)
Next Qtr
(11/2021)
Consensus Estimate $-0.46 $-0.22
# of Estimates 3 3
High Estimate $-0.33 $-0.03
Low Estimate $-0.55 $-0.33
Year Ago EPS $-0.25 $0.08
Year Over Year Growth Estimate 88.20% -367.59%
Current Yr
(02/2022)
Next Yr
(02/2023)
Consensus Estimate $-0.63 $-1.10
# of Estimates 3 2
High Estimate $-0.31 $-0.23
Low Estimate $-0.83 $-1.97
Year Ago EPS $-0.15 $-0.63
Year Over Year Growth Estimate 321.56% 73.78%
Current Qtr
(08/2021)
Next Qtr
(11/2021)
Current Year
(02/2022)
Next Year
(02/2023)
Consensus Estimate $-0.46 $-0.22 $-0.63 $-1.10
# of Estimates 3 3 3 2
High Estimate $-0.33 $-0.03 $-0.31 $-0.23
Low Estimate $-0.55 $-0.33 $-0.83 $-1.97
Year Ago EPS $-0.25 $0.08 $-0.15 $-0.63
Year Over Year Growth Estimate 88.20% -367.59% 321.56% 73.78%

Insider Information Summary

as of 08/31/2021
% Insiders - 3.03%
% Remaining Total Shares - 96.97%
Current 1 Month
Net Insider Transaction 445.71 K 485.81 K
Shares Bought 566.32 K 566.32 K
Shares Sold 120.62 K 80.52 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Elon Musk Starlink Lead

SpaceX CEO Elon Musk Says Starlink Exits Beta Next Month

SpaceX CEO Elon Musk says the company’s Starlink high-speed internet service will come out of beta testing next month.

Wall Street Lead

Cramer: Using Short-Term Moves to Tweak Your Portfolio

Whether the news is good or bad, you can take advantage of it if you understand why you're involved in a stock in the first place.

10. Chemical & petrochemical pharma sh

Jensen: These Three Healthcare Stocks Are Worth a Look

Just because we're in the market's worst month of the year doesn't mean there aren't good investments available.

18. Apple Inc. (AAPL)

Parus Files Second Patent Infringement Lawsuit Against Apple

Parus files a second patent infringement lawsuit against Apple, alleging it infringed on its patents for voice-browsing and device control technology.

12. Software engineer

Business Software Provider AvidXchange Files for IPO

Accounts payable software provider AvidXchange on Friday filed for a initial public offering.

9/11 Lead

Cramer’s Recollections of 9/11

A beautiful day in New York City, Then the Unimaginable

Hong Kong Stocks Slump On Tech Sector Worries As US Official Signals Flaws In China Trade Deal

Intraday Reversals Signal Struggles for Market

But James "Rev Shark" Deporre says the trading action is both normal, and appropriate for September, and he's been adding some names to his portfolio.

stocks market index sh

Cramer's Mad Money Recap: FedEx, Costco, Nike

Jim Cramer says this is a rough season for stock, and investors need to take defensive action.

anxiety grocery mask sh

Jensen: Economy Has a Bearish Outlook

Real Money's Bret Jensen says a slower-than-expected pandemic recovery is a warning for the stock market.

Pfizer vaccine Lead

FDA Panel Recommends Covid Booster Shots for 65, Older and Those at High Risk

Food and Drug Administration's advisory panel on Friday voted to recommend Covid-19 booster shots of the Pfizer vaccine for a limited section of the population.